Australian biotech market watch 30/09/09
Wednesday, 30 September, 2009
A rather flat day on the markets on this last day of September, with the All Ordinaries sitting around the 4,746 mark as of 2:00pm this afternoon and the heath care indices following suit.
Of the Big Three, bionic ear pioneer, Cochlear (ASX:COH) is up a modest 63c to $67.39 and ResMed (ASX:RMD) remains flat at $5.17. CSL (ASX:CSL), which has been in the news of late with controversy over the national rollout of H1N1 vaccines, is down 36c, or 1.1% to $33.39.
Ansell (ASX:ANN) managed to lift by 1.62% to $10.06 in low volume trading after a rather flat couple of weeks.
The only other movers are Fisher & Paykel Healthcare, up 1.9% to $2.69, recovering some of the losses it's experienced since its high of $2.80 at the beginning of September, and Sonic Healthcare, up 38c to $14.24, which is 3.8% for the week.
Eye disease specialist, pSivida (ASX:PVA), dropped 57c to $4.95 after it announced early safety and efficacy results of its drug Iluvien, which proved "promising".
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
